Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present KalVista Pharmaceuticals, Inc. (NASDAQ: KALV).

Full DD Report for KALV

You must become a subscriber to view this report.


Recent News from (NASDAQ: KALV)

KalVista Pharmaceuticals Recognizes HAE Day
– A Global Awareness Day for a Rare Life-Threatening Condition – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced rec...
Source: Business Wire
Date: May, 16 2018 07:30
Institutional Top Ideas Series: Ra Capital Management
In the last entry of this series we took a look at top ideas from Orbimed Advisors, a large fund in the midst of a leadership transition which avoids outsized bets (over 5% weighting) yet still has posted decent returns. Going forward, I hope to continue to delve into the portfolios of su...
Source: SeekingAlpha
Date: May, 10 2018 02:04
Detailed Research: Economic Perspectives on CASI Pharmaceuticals, Energy Transfer Partners, Cypress Semiconductor, Xcel Energy, Ironwood Pharmaceuticals, and KalVista Pharmaceuticals - What Drives Growth in Today's Competitive Landscape
NEW YORK, May 07, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Energy Transfer Partners, L.P. (...
Source: GlobeNewswire
Date: May, 07 2018 07:30
KalVista Pharmaceuticals Presents Data at The Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting
– Oral Plasma Kallikrein Inhibitor Blocks VEGF-induced Retinal Vascular Hyperpermeability – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhi...
Source: Business Wire
Date: May, 02 2018 07:30
KalVista Pharmaceuticals to Present Data at The Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting
– Oral Plasma Kallikrein Inhibitor Data in a Preclinical Model of Retinal Edema to be Presented – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule proteas...
Source: Business Wire
Date: April, 18 2018 07:30
Wired News - Sangamo Therapeutics' Preclinical Study Data from MPS II in Vivo Genome Editing Program Published in Molecular Therapy
Stock Monitor: KalVista Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 6, 2018 / Active-Investors.com has just released a free research report on Sangamo Therapeutics, Inc. (NASDAQ: SGMO ). If you want access to this report all you need to do is sign up now by clicki...
Source: ACCESSWIRE IA
Date: April, 06 2018 07:05
Kalvista Pharmaceuticals reports Q3 results
Kalvista Pharmaceuticals (NASDAQ: KALV ): Q3 EPS of -$0.49 More news on: Kalvista Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: March, 16 2018 07:34
New Research Coverage Highlights KalVista Pharmaceuticals, Forestar Group, Unum Group, 22nd Century Group, Chevron, and The Michaels Companies - Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), Forestar Group Inc (NYSE:F...
Source: GlobeNewswire
Date: March, 05 2018 07:50
KalVista Pharmaceuticals to Present at 30th Annual ROTH Conference
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present a corporate overview at the ROTH Conference on Monday, March 12, 201...
Source: Business Wire
Date: March, 05 2018 07:30
Week 5 Breakout Forecast:  Short-Term Picks To Give You An Edge
Breakout Forecast Selections for Week 5: This week I have selected two of the 8 breakout stocks to share from the subscription Breakout Portfolio. Healthcare biotechnology and technology stocks were the largest representation of breakout stocks in my screener for this week. I continue to ...
Source: SeekingAlpha
Date: January, 28 2018 01:31

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-178.978.859.028.659138,132

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-241,8712,32180.6118Short
2018-05-232,6165,40448.4086Short
2018-05-225,56111,53248.2223Short
2018-05-212,3826,77735.1483Short
2018-05-182,94111,00926.7145Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on KALV.


About KalVista Pharmaceuticals, Inc. (NASDAQ: KALV)

Logo for KalVista Pharmaceuticals, Inc. (NASDAQ: KALV)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $97,378,973 - 05/11/2018
  • Issue and Outstanding: 10,795,895 - 03/01/2018

 


Recent Filings from (NASDAQ: KALV)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 16 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: March, 16 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: March, 13 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 12 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 14 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: December, 14 2017
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: November, 13 2017
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: October, 20 2017

 

 


Daily Technical Chart for (NASDAQ: KALV)

Daily Technical Chart for (NASDAQ: KALV)


Stay tuned for daily updates and more on (NASDAQ: KALV)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: KALV)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in KALV is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of KALV and does not buy, sell, or trade any shares of KALV. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/